Magna International Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Magna International Inc. Common Stock trades at $64.38 (market cap $17.39B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Magna International Inc. Common Stock is the larger of the two by market cap, and Magna International Inc. Common Stock pays a 3.03% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Magna International Inc. Common Stock for 6 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| MGA | PCVX | |
|---|---|---|
Market Cap | $17.39B | $10.51B |
Volume | 1,279,527 | 2,644,694 |
Sector | Consumer Cyclical | Health |
52-Week High | $73.05 | $73.82 |
52-Week Low | $44.65 | $40.32 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $22.42B | $9.14B |
Dividend Yield | 3.03% | — |
Signals from Pluang's Aura AI — not financial advice
Magna International (MGA) trades at $65.31, up 2.75% with a bullish technical signal. The stock shows strong earnings momentum with three consecutive quarterly beats and trades at attractive valuations with P/E of 24.01 and P/S of 0.43. Recent news highlights margin expansion and international growth opportunities, while cash flow remains positive despite increased capital returns.
MGA presents a favorable risk-reward profile with analyst consensus target of $69.20 (5.9% upside) and 43% buy ratings. Key catalysts include Q3 2026 earnings on October 30 and continued margin improvement, though risks include flat auto production and potential tariff impacts on North American operations.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Magna International Inc. is a Canada-based automotive supplier that designs, engineers, and manufactures vehicle systems and components, including body and chassis structures, seating, powertrain, and electronics, and provides complete-vehicle engineering and contract assembly, with manufacturing operations in 28 countries.
Read more on MGA →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →